This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

DISPATCH® Hospital Cleaner Disinfectant With Bleach Portfolio U.S. EPA Registered To Kill C. Difficile Spores In Five Minutes -- The Fastest Contact Time Available

WASHINGTON, Sept. 27 /PRNewswire-FirstCall/ -- The Clorox Company (NYSE: CLX) announced today at the Annual Conference and Healthcare Marketplace of the American Society for Healthcare Environmental Services (ASHES) that the U.S. Environmental Protection Agency (EPA) approved the registration of DISPATCH® Hospital Cleaner Disinfectant with Bleach portfolio to kill Clostridium difficile spores in five minutes(1), the fastest contact time available.

The DISPATCH® portfolio contains the first bleach-based sprays registered to kill C. difficile spores(2), and the premixed, ready-to-use liquids are similar to the 1:10 bleach solution strength that is recommended by the Centers for Disease Control and Prevention (CDC) for effective disinfecting. DISPATCH® liquids contain an anticorrosive ingredient that makes it less damaging to surfaces of equipment.  The DISPATCH® liquids are multipurpose, broad-spectrum cleaner disinfectants for use on hard, nonporous surfaces.

"Clorox is committed to providing the best portfolio of bleach products to kill C. difficile," said Craig Stevenson, vice president and general manager, Clorox Away From Home Division.  "The science shows that when deployed as part of a comprehensive C. difficile prevention program, bleach is proven to kill C. difficile spores.  In the fast-paced hospital environment, we know it is critical for healthcare staff to work quickly and efficiently.  The DISPATCH portfolio has the fastest EPA-registered kill time currently available for C. difficile spores(3) and its ready-to-use format also delivers on speed because the liquids don't require any mixing."

The DISPATCH® portfolio offering is part of a comprehensive C. difficile solution program offered by Clorox.  The company also offers a C. difficile Prevention Kit featuring a protocol and checklist for terminal cleaning of C. difficile isolation rooms, information on bleach efficacy when it comes to fighting C. difficile spores, a calculator estimating the financial impact on C. difficile on acute care facilities and C. difficile prevention training and education videos.

C. Difficile is a Top Priority in Healthcare Facilities as Incidence Increases Annually

In a recent survey of acute care facilities, infection preventionists say that C. difficile is their top pathogen of concern.(4) In the U.S., more than 28,000 people die from C. difficile(5), and there are approximately 500,000 C. difficile infections annually.(6) A recent Association for Professionals in Infection Control (APIC) survey found C. difficile infections cost U.S. healthcare facilities $17.6 million to $51.6 million every day.(7)

A comprehensive and coordinated approach to preventing the spread of infection in the healthcare setting includes proper surface disinfection and commitment to precautionary measures. Leading infection prevention and healthcare industry leaders recommend and support the use of bleach-based solutions to kill C. difficile spores as part of a broader prevention program. In fact, 8 out of 10 hospitals are currently using bleach or bleach-based products when C. difficile is detected.(8)

"In the hospitals in which I have worked, bleach has been used for years to help reduce the incidence of C. difficile infection," said Lillian Burns, MT, MPH, CIC, the director of infection control and epidemiology at Staten Island University Hospital.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs